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Abstract Afatinib (also known as BIBW 2992) has recently
been approved in several countries for the treatment of a
distinct type of epidermal growth factor receptor (EGFR)-
mutated non-small cell lung cancer. This manuscript compre-
hensively reviews the preclinical data on afatinib, an irrevers-
ible inhibitor of the tyrosine kinase activity of members of the
epidermal growth factor receptor family (ErbB) including
EGFR, HER2 and ErbB4. Afatinib covalently binds to cyste-
ine 797 of the EGFR and the corresponding cysteines 805 and
803 in HER2 and ErbB4, respectively. Such covalent binding
irreversibly inhibits the tyrosine kinase activity of these recep-
tors, resulting in reduced auto- and transphosphorylation with-
in the ErbB dimers and inhibition of important steps in the
signal transduction of all ErbB receptor family members.
Afatinib inhibits cellular growth and induces apoptosis in a
wide range of cells representative for non-small cell lung
cancer, breast cancer, pancreatic cancer, colorectal cancer,
head and neck squamous cell cancer and several other cancer
types exhibiting abnormalities of the ErbB network. This
translates into tumour shrinkage in a variety of in vivo rodent
models of such cancers. Afatinib retains inhibitory effects on
signal transduction and in vitro and in vivo cancer cell growth
in tumours resistant to reversible EGFR inhibitors, such as
those exhibiting the T790M mutations. Several combination
treatments have been explored to prevent and/or overcome
development of resistance to afatinib, the most promising
being those with EGFR- or HER2-targeted antibodies, other
tyrosine kinase inhibitors or inhibitors of downstream signal-
ling molecules.
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EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ERK Extracellular signal-regulated kinase
HNSCC Head and neck squamous cell cancer
mTOR Mammalian target of rapamycin
NSCLC Non-small cell lung cancer
PI3K Phosphatidyl-inositol-3-kinase
STAT Signal transducers and activators of transcription
TGF-α Transforming growth factor-α
TKI Tyrosine kinase inhibitor
Introduction
Epidermal growth factor (EGF), first described in 1962
(Cohen 1962), is a 53 amino acid peptide (Savage et al.
1972) which serves as an auto- and/or paracrine stimulator
of cell growth, proliferation and differentiation. Its discovery
was awarded in 1986 with the Nobel Prize in Physiology and
Medicine to Stanley Cohen and Rita Levi-Montalcini. The
receptor for EGF is called epidermal growth factor receptor
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(EGFR) and has been found overexpressed in many types of
cancer (Modjtahedi and Dean 1994), where it mainly pro-
motes proliferation and survival of malignant cells and, by
inducing expression of angiogenic growth factors and metal-
loproteinases, promotes tumour vascularization and metasta-
sis (De Luca et al. 2008). The identification of EGF and its
receptor resulted in the discovery of three other members of
the EGFR (also called HER or ErbB) family and their cognate
ligands. These in turn led to the development of several
therapeutic strategies against these receptors for use in the
targeted therapy of human cancers (Ioannou et al. 2012;
Zhang et al. 2007).
Structure and function of ErbB family members
EGF affects cell function by binding to specific cell surface
receptors which are part of the ErbB family (Holbro and
Hynes 2004). Besides EGF, endogenous ErbB ligands include
amphiregulin, transforming growth factor-α (TGF-α), epigen,
epiregulin, heparin-binding EGF-like growth factor,
neuregulin 1-4, neuroglycan, tomoregulin and betacellulin.
The ErbB receptor family contains four closely related mem-
bers, which are termed EGFR1 (also known as ErbB1 or
HER1), HER2 (also known as ErbB2 or neu), ErbB3 (also
known as HER3) and ErbB4 (also known as HER4) (Ioannou
et al. 2012). ErbB family members are characterized by an
extracellular ligand-binding domain, a transmembrane region
and an intracellular domain with intrinsic tyrosine kinase
activity. The crystal structures of the kinase domain of the
EGFR have been reported (Kumar et al. 2008), including
those with G719S, T790M and L858R mutations (Yasuda
et al. 2012). The three-dimensional structures of the extracel-
lular domain of some ErbB members have also been deter-
mined (Burgess et al. 2003) and revealed some insight on how
this family of receptors gets activated and transduces extra-
cellular signals to the cell interior.
Key to signal transduction is the mandatory formation of
ErbB homo- or heterodimers. Upon agonist binding, EGFR,
ErbB3 and ErbB4 undergo a conformational change which
exposes sites for receptor dimerization. In general, ligand-
induced ErbB receptor ectodomain dimerization triggers the
formation of intracellular asymmetric kinase dimers in which
the C-lobe of the activating monomer engages the N-lobe of
the acceptor monomer (Zhang et al. 2006). In such dimers, the
activating monomer acts as an allosteric activator by
pushing the C-helix in the correct position for catalysis.
Molecular promiscuity of the ErbB kinase domains re-
sults in transphosphorylation of C-terminal regulatory
tyrosine residues in the intracellular domain of the acti-
vating kinase which acts as a substrate for the acceptor
monomer. These phosphotyrosines become attachment
sites for downstream signalling molecules, hence trans-
ducing signals from the cell surface to the nucleus via
the Ras/extracellular signal-regulated kinase (ERK) path-
way, the phosphatidyl-inositol-3-kinase (PI3K)/Akt path-
way and signal transducers and activators of transcription
(STAT) pathways (Kumar et al. 2008).
Interestingly, the HER2 ectodomain, for which a ligand has
never been identified, is poised in an “active like” conforma-
tion. Therefore, HER2 is believed to act as the preferred
dimerization partner for other ErbB family members (Graus-
Porta et al. 1997).
ErbB3 on the other hand has three cognate ligands
(neuregulin 1 and 2 and neuroglycan) but is distinct from
other ErbB family members with respect to weak intrinsic
tyrosine kinase activity due to structural diversity at critical
catalytic residues in the kinase domain (Shi et al. 2010).
Accordingly, ErbB3 works as a signalling entity only after
heterodimerization with other ErbB receptor molecules
(Holbro and Hynes 2004).
ErbB4, the fourth member in this family, exhibits complex
signal transduction modalities. This receptor molecule can be
expressed in four functionally variant isoforms (Hollmen and
Elenius 2010). Two isoforms differ in the extracellular
juxtamembrane domain (JM-a and JM-b) and two in the
intracellular domain (CYT-1 and CYT-2). The CYT-1 isoform
for instance contains a 16 amino acid insert exhibiting several
binding sites for PI3K, while the CYT-2 isoform cannot
couple to the PI3K pathway because it lacks the necessary
YPTM binding sites. The JM-a and JM-b isoforms are also
alternative splice variants. When compared to the three other
variants, the longer JM-a molecule differs significantly in its
mode of signal transduction and is characterized by the pres-
ence of specific residues that can be cleaved by the TNFα
converting enzyme TACE. As a result, the ectodomain of
ErbB4 is being shed and the truncated membrane-bound
intracellular domain of ErbB4 (m80) becomes a substrate of
γ-secretase. These two sequential proteolytic steps generate
an intracellular ErbB4 variant known as s80 that translocates
to the nucleus and acts as a transcriptional co-activator and co-
repressor by interacting with transcription factors such as
STAT5, YAP, ER, ETO2 or TAB2-NcoR. The large plasticity
of the ErbB receptor system, which involves at least 13
different ErbB ligands and at least four different receptors
excluding splice variants, results in a sophisticated signalling
network with output control at multiple levels (Roskoski
2014; Yarden and Sliwkowski 2001).
The importance of ErbB family members in cancer biology
ErbB receptors are expressed in many cell types of epithelial,
mesenchymal and neuronal origin (Zhang et al. 2007). They
exhibit aberrant signal transduction in many types of solid
1 Some investigators use the term EGFR for the entire class of ErbB
proteins. In line with most others, we here use it only for ErbB-1/HER1.
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human cancers, including non-small cell lung cancer
(NSCLC), breast cancer (BC), bladder cancer, ovarian cancer,
colorectal cancer, pancreatic cancer and head and neck squa-
mous cell cancer (HNSCC) (Ciardiello and Tortora 2008;
Ioannou et al. 2012; Khelwatty et al. 2013). This exaggerated
signalling may involve an enhanced signal input due to in-
creased exposure to ErbB ligands (Modjtahedi and Dean
1994; Zhang et al. 2007). Secondly, tumour cells can overex-
press ErbB receptors, due for instance to an increased gene
copy number (Ciardiello and Tortora 2008) or defective
down-regulation (Pareja et al. 2012). Thirdly, cancer cells
may harbour mutations in EGFR, HER2 or ErbB4 (see be-
low). The ErbB family members are involved not only in cell
proliferation but also several other processes regulating tu-
mour progression, such as cell motility, cell adhesion and
angiogenesis (Zhang et al. 2007). Hence, overexpression of
EGF receptors or deregulation of their activity is typically
associated with the degree of malignancy of the disease and
a poor prognosis.
HER2 was the first member in the ErbB family to be
associated with epithelial cancers. The HER2 protein appears
overexpressed in a variety of carcinomas including but not
limited to BC, NSCLC and ovarian, gastric and salivary gland
cancer (Heiser et al. 2012). ERBB2 gene amplification is
driving protein overexpression in 18–25 % of BC cases. BC
overexpressing HER2 are clinically more aggressive than
those exhibiting normal numbers of HER2 protein at the cell
surface (Press et al. 1990). While less abundant, cancer driv-
ing HER2 mutations have also been described in NSCLC
(Shigematsu et al. 2005) and breast cancer (Bose et al. 2013).
EGFR mutations have been characterized best in NSCLC,
where they represent early genetic events in cancer develop-
ment, which are of fundamental relevance for the biology of
these tumours (Gazdar 2009; Hammerman et al. 2009).
Activating EGFR mutations are found in the ectodomain as
well as in the ATP-binding pocket of the tyrosine kinase
domain and led to aberrant activation. Kinase domain muta-
tions are grouped into three classes (Gazdar 2009). Class I
mutations are in-frame deletions within exon 19, almost al-
ways including a loss of amino acid residues 747–749 and
accounting for 40 % of all EGFR mutations. Class II muta-
tions are non-synonymous single nucleotide substitutions,
most often replacing a leucine for arginine in codon 858
(L858R); other class II mutations exist (e.g. G719X) but are
much less common. Class III mutations are in-frame duplica-
tions or insertions in exon 20. Interestingly, EGFR mutations
are typically exclusive with KRAS and BRAF mutations, at
least in lung cancer, and tumours exhibiting one of the latter
two are relatively insensitive to EGFR inhibitors (Lin and
Bivona 2012).
Oncogenic mutants also exist in other ErbB family mem-
bers, but occur less frequently. For HER2, they mostly repre-
sent in-frame duplications or insertions in an eight-codon
region of exon 20. Transgenic mice with inducible expression
of the most common HER2 mutation, an in-frame YVMA
insertion at residue M774, in mouse lung epithelium exhibit
invasive adenosquamous cancer restricted to proximal and
distal bronchioles (Perera et al. 2009). ErbB3 mutations have
recently been reported in ~11 % of colon and gastric cancers
(Jaiswal et al. 2013). Interestingly, the oncogenic activity of
the ErbB3 mutants remains dependent on kinase active ErbB2
and was found to be effectively blocked by ErbB targeting
antibodies or small molecule inhibitors. The majority of the
mutations identified clustered in the extracellular domain,
although some were found to map to the intracellular kinase
domain. ErbB4 mutations have been described to occur in
lung, breast, gastric cancer and melanoma and like for ErbB3
differ from those observed in EGFR or HER2 by not
displaying characteristic mutational hotspots. Several of these
ErbB4 mutations were shown to be oncogenic in melanoma
models (Prickett et al. 2009).
ErbB receptor inhibitors
Due to the importance of the ErbB family of receptors in
tumour progression and poor response to the conventional
therapies, intensive efforts have been devoted to identify and
develop inhibitors for ErbB receptors (see Table 1).
One approach has focused on monoclonal antibodies
against ErbB family members which interact with the extra-
cellular domains. These included cetuximab (Horn and
Sandler 2009) and panitumumab, targeting EGFR, as well as
trastuzumab (Wong and Lee 2012) and pertuzumab, which
target HER2. Originally, multiple anti-HER2 therapies rang-
ing from therapeutic antibodies (Park et al. 1992) to antibody
drug conjugates (Boyraz et al. 2013), small molecule inhibi-
tors such as lapatinib (Hurvitz and Kakkar 2012) and liposo-
mal vectors containing the E1A tumour suppressor known to
repress the expression of HER2 as gene therapy option (Yoo
et al. 2001) were simultaneously developed. The data from
five clinical trials using trastuzumab in BC patients whose
tumours overexpress HER2 ultimately led to the registration
of trastuzumab in 1998 as the first anti-ErbB-targeted agent
which has become nowadays the mainstay of therapy in
HER2-positive BC (Perez et al. 2011).
Another approach was based on small molecules which
directly bind to the tyrosine kinase domain of ErbB receptors
and act as tyrosine kinase inhibitors (TKIs). The first repre-
sentatives of this class, gefitinib, erlotinib and lapatinib, were
reversible EGFR or EGFR/HER2 selective TKI inhibitors
(Horn and Sandler 2009). These agents are initially effective
in many patients but resistance may develop upon prolonged
treatment. Irreversible ErbB family TKIs were developed in
the hope that they may provide superior and more sustained
efficacy as they inhibit all oncogenic homo- and heterodimers
(Barf and Kaptein 2012).
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In general, tumours which are not driven by a particular
ErbB deregulation are not sensitive tomonotherapy with ErbB
targeting agents. In NSCLC patients with tumours displaying
EGFR mutations, EGFR-TKIs have proven to be a very
effective treatment option. Some rare EGFR mutations (e.g.
class III exon 20 insertions), which are known to be activating,
unfortunately show poor sensitivity to erlotinib or gefitinib
and are one cause for primary resistance to these agents in
EGFR mutant NSCLC patients (Vadakara and Borghaei
2012).
While gefitinib and erlotinib are initially effective in the
majority of NSCLC patients with common EGFR mutations
(exon 19 deletions and L858R point mutations), acquisition of
resistance invariably occurs. Secondary or acquired resistance
is the major limitation to the long-term use of ErbB TKIs. The
two major mechanisms for the development of resistance
during treatment are the occurrence of tumour cell clones
which carry additional EGFR mutations or additional genetic
alterations that can co-occur with EGFR-activating mutations
(Lin and Bivona 2012). The latter include amongst others
mutations in key molecular switches that control the activity
of the PI3K/Akt pathway, insulin-like growth factor-1 recep-
tor signalling or NF-κB signalling (Engelman and Settleman
2008; Guix et al. 2008; Sequist et al. 2011).
The most frequently occurring secondary EGFR mutation
in lung cancer is an exchange of a threonine for a methionine
in position 790 (T790M) in exon 20; it is present in about
50 % of all cancers with acquired resistance to EGFR-TKIs
(Engelman and Settleman 2008) but very rare in untreated
NSCLC (Chmielecki et al. 2012). Additional mutations
known to be resistant to gefitinib and erlotinib have also been
described and are largely confined to exon 19 and 20, e.g.
D761Y, L747S or T854A, and remain apparently rare
(Nguyen et al. 2009; Yasuda et al. 2012). Thus, preventing
or overcoming ErbB receptor inhibitor resistance with a
new generation of ErbB inhibitors promises to increase
the durability of treatment. Compounds in clinical de-
velopment are dacomitinib, neratinib, HM781-36B, AZ
9192 and CO-1686.
Afatinib (Giotrif®), also known as BIBW 2992 (N-[4-[(3-
chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-
furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-
butenamide; Fig. 1), is an ATP-competitive anilinoquinazoline
derivative harbouring a reactive acrylamide group, capable of
covalent binding to and irreversible inhibition of EGFR, HER2
and HER4 (Solca et al. 2012). It has recently been approved in
several countries for the treatment of a distinct type of EGFR-
mutated non-small cell lung cancer (NSCLC). This manuscript
comprehensively reviews the available non-clinical data on
afatinib, whereas clinical data in the treatment of NSCLC
(Nelson et al. 2013) and other cancer types (Harbeck et al.
2014) have recently been summarized elsewhere.
Effects at the molecular level
To explore the direct molecular interaction between ErbB
family members and their inhibitors, two types of approach
have been used. The most direct one is based on generating
crystal structures of the receptor in an inhibitor-bound state
(Solca et al. 2012). Amore indirect approach uses information
from the former as well as data on functional potency of
various inhibitors to perform computer-based modelling of
the interaction, also known as docking studies, which can be
reasonably predictive (La Motta et al. 2009). A docking study
of the T790M resistance mutation of the EGFR reported that
afatinib binds to a pocket in the catalytic domain including the
amino acids Met766, Phe856 and Met790 (Nie et al. 2012).
More evidence comes from the analysis of the crystal structure
of the afatinib/EGFR kinase domain complex obtained at a
2.8-Å resolution (Solca et al. 2012). This revealed a hydrogen
bond with Met793 and a covalent bond between Cys797 and
the Michael-acceptor group of afatinib. Covalent binding
Table 1 Potency of afatinib and
other compounds to inhibit tyro-
sine kinase activity of ErbB fam-
ily members including important
mutations of EGFR. Data are
shown as the range of the
nanomolar concentration causing
50 % inhibition and are adapted
from Solca et al. (2012)
EGFRWT EGFRL858R EGFRL858R/T790M HER2 ErbB4
Afatinib 0.2–0.7 0.2–0.4 9–10 7–25 0.7–1.7
Canertinib 0.3–1.7 0.4–0.8 18–36 22–72 0.8–10
Erlotinib 0.9–1.7 1.1–2.7 1,520–3,562 238–698 579–756
Gefitinib 0.4–4.7 0.8–1.4 534–1,267 416–1,830 293–323
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typically leads to irreversible inhibition, as confirmed with
afatinib in intact cells (see next section).
To further explore the covalent binding of afatinib to ErbB
receptors, wild-type EGFR, the L858R/T790M EGFR, HER2
and HER4 were incubated with afatinib and digested with
pepsin; the resulting digests were separated by liquid chroma-
tography and analysed by mass spectrometry (Solca et al.
2012). These data confirmed the covalent binding of afatinib
to EGFR at Cys797 and indicated covalent binding to the
corresponding Cys805 and Cys803 in HER2 and ErbB4,
respectively.
The functional consequences of afatinib binding to ErbB
Family receptors have been studied at the molecular level by
measuring inhibition of tyrosine kinase activity in cell-free
assays. In such experiments, afatinib showed nanomolar po-
tency to inhibit EGFR, HER2 and ErbB4 (ErbB3 was not
studied as it has much weaker tyrosine kinase activity); at each
of those receptors, the potency of afatinib was similar to or
greater than that of canertinib, erlotinib, gefitinib and lapatinib
(Table 1) (Li et al. 2008; Solca et al. 2012). The high potency
of afatinib to inhibit EGFR, HER2 and ErbB4 and superiority
to gefitinib was confirmed by other investigators (Nam et al.
2011; Sos et al. 2010).
The high potency of afatinib to inhibit the tyrosine kinase
activity of wild-type EGFR was fully maintained on EGFR
with the activating L858R mutation (Solca et al. 2012; Sos
et al. 2010). The potency of afatinib on the L858R/T790M
double mutation of EGFR, known to be resistant to erlotinib,
gefitinib and lapatinib, was reduced but still in the nanomolar
range (Table 1) (Cha et al. 2012; Solca et al. 2012; Sos et al.
2010). When tested in a panel of 52 other tyrosine and serine/
threonine kinases, afatinib only inhibited the kinase activity of
ErbB family members (Li et al. 2008). The selectivity of
afatinib was confirmed by independent investigators assessing
the binding properties of afatinib in 442 kinases covering
more than 80 % of the human kinome (Davis et al. 2011): it
interacted significantly (low nanomolar range; 0.25 nM<Kd<
6.3 nM) only with EGFR, HER2 and ErbB4; except for GAK,
BLK, IRAK1, EpHA6, HIPK4, PhKG2 and phosphorylated
Abl-1 kinase (79 nM<Kd<570 nM), all other Kd values were
above 1,000 nM, illustrating the high selectivity of afatinib on
the human kinome.
Effects at the cellular level
Studies at the cellular level have been performed to explore
two main questions:
– How does afatinib affect intracellular signal transduction
in cancer cells?
– What are the effects of afatinib on cancer cell growth and
apoptosis?
Effects on signal transduction
The covalent modification of the EGFR, HER2 and ErbB4
kinase domain by afatinib indicates irreversible inhibition of
their enzymatic activity. For EGFR, this was directly con-
firmed by experiments demonstrating that kinase activity
remained inhibited for several hours following afatinib treat-
ment of cell lines for a short time and subsequent washout
(Solca et al. 2012). The irreversibility of afatinib effects was
independently confirmed for both EGFR and HER2 based on
autophosphorylation experiments (Cha et al. 2012).
The first step in the activation of ErbB receptors is ligand-
induced dimerization leading to ErbB receptor homo- or het-
erodimers and subsequent transphosphorylation of tyrosine
residues in the C-terminus of the donor kinase domain by
the acceptor kinase (Fig. 2) (Zhang et al. 2006). Inhibition of
autophosphorylation by afatinib has been shown for EGFR
(Ioannou et al. 2013; Kim et al. 2012b; Ninomiya et al. 2013;
Solca et al. 2012; Takezawa et al. 2012; Tanaka et al. 2012),
HER2 (Canonici et al. 2013; Ninomiya et al. 2013; Solca et al.
2012; Tabara et al. 2012; Takezawa et al. 2012; Tanaka et al.
2012), ErbB4 (Solca et al. 2012) and transphosphorylation of
ErbB3 (Ioannou et al. 2013; Kim et al. 2012b; Tabara et al.
2012; Takezawa et al. 2012; Tanaka et al. 2012) in a wide
variety of cell lines representing lung (Kim et al. 2012b; Lee
et al. 2013; Ninomiya et al. 2013; Solca et al. 2012; Tabara
et al. 2012; Takezawa et al. 2012), breast (Solca et al. 2012),
gastric (Tanaka et al. 2012), colorectal (Khelwatty SA,
Essapen S, Seddon A, Modjtahedi H, in preparation) and
pancreatic cancer (Ioannou et al. 2013). Similar to the kinase
inhibition studies, afatinib’s potency for inhibition of auto-
phosphorylation was in the low nanomolar range. Moreover,
inhibition of autophosphorylation was demonstrated not only
in cells expressing wild-type EGFR but also in those contain-
ing EGFR mutations including L858R (Li et al. 2008),
T790M (Lee et al. 2013; Takezawa et al. 2012) and L858R/
T790M (Lee et al. 2013; Li et al. 2008; Solca et al. 2012).
Moreover, afatinib inhibits not only the spontaneous or EGF-
induced autophosphorylation of EGFR but also that stimulat-
ed by TGF-α (Lee et al. 2013). Inhibition of EGFR phosphor-
ylation was also shown for the afatinib/nintedanib combina-
tion in a colorectal cancer cell line (Poindessous et al. 2011).
Moreover, inhibition of EGFR and HER2 phosphorylation
was also demonstrated upon in vivo treatment with afatinib
in mice harbouring an adenosquamous lung carcinoma, and
this inhibition was further enhanced in combination with
rapamycin (Li et al. 2008; Perera et al. 2009).
The inhibitory effects of afatinib have also been explored at
the next level of ErbB receptor signalling, i.e. inhibition of
downstream signalling pathways such as the Ras/ERK,
PI3K/Akt and STAT pathways. Inhibition of ERK activation
was reported in cell lines derived from cancers of the lung
(Kim et al. 2012b; Lee et al. 2013; Mack et al. 2013;
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Ninomiya et al. 2013; Tabara et al. 2012; Takezawa et al.
2012), breast (Canonici et al. 2013), stomach (Tanaka et al.
2012) and pancreas (Ioannou et al. 2013). Inhibition of Akt
activation was reported in cell lines derived from cancers of
the lung (Kim et al. 2012b; Lee et al. 2013; Mack et al. 2013;
Ninomiya et al. 2013; Tabara et al. 2012; Takezawa et al.
2012), stomach (Tanaka et al. 2012) and pancreas (Ioannou
et al. 2013). Where concentration-response curves were re-
ported, pathway inhibition was observed at low nanomolar
concentrations. Such inhibition was additive or even synergis-
tic with that by cetuximab (Takezawa et al. 2012) or by
inhibitors of insulin-like growth factor-1 (Ioannou et al.
2013). Inhibition of signal transduction by afatinib was also
reported in cells harbouring the EGFRT790Mmutation (Kim
et al. 2012b; Lee et al. 2013; Takezawa et al. 2012) or cells
resistant to gefitinib (Ninomiya et al. 2013) or erlotinib (Mack
et al. 2013; Tabara et al. 2012). Afatinib also inhibited activa-
tion of additional signal transduction molecules such as the
protein kinases p38, rsk1 and p70S6 (Mack et al. 2013). The
relevance of the in vitro studies on ERK, Akt and p70S6 was
confirmed in vivo in mice harbouring an adenosquamous lung
carcinoma, where the inhibitory effects of afatinib were fur-
ther enhanced in combination with rapamycin (Perera et al.
2009).
In conclusion, these data demonstrate that afatinib irrevers-
ibly inhibits important steps in the signal transduction of all
members of the ErbB receptor family, which include inhibi-
tion of phosphorylation of the receptors themselves and that of
downstream signal transduction molecules such as ERK and
Akt.
Effects on cellular growth and apoptosis
The ability of afatinib to inhibit the growth of cancer cells
in vitro has been studied in a broad panel of cell lines
representing various types of cancer (effects on cell lines
harbouring ErbB receptor resistance mutations or being phe-
notypically resistant to other anti-cancer agents will be
Fig. 2 Schematic representation of activation, signalling and targeting of
ErbB receptor family members. Overexpression or mutation of ErbB
family members (EGFR, HER2, ErbB3 or ErbB4) or overexpression/
translocation of ErbB growth factors results in the formation of ErbB
homo- and heterodimers; for simplicity only, one heterodimer
(EGFR:HER2) is shown here but all homo- and heterodimer combina-
tions between the four monomers are possible. Dimerization leads to the
formation of asymmetric head-to-tail complexes of the intracellular ki-
nase domains resulting in transphosphorylation and receptor dimer
activation resulting in downstream signalling. ErbB pathway engagement
increases cell proliferation, angiogenesis, migration, metastasis and inva-
sion, reduction of apoptosis and/or resistance to radiation and chemother-
apy. Anti-ErbB monoclonal antibodies can be directed against EGFR
(e.g. cetuximab and panitumab), HER2 (e.g. pertuzumab and
trastuzumab) or ErbB3 (e.g. MM121). Small molecule TKIs can be
EGFR-specific (e.g. erlotinib and gefitinib), dual EGFR/HER2 (e.g.
lapatinib) or pan-ErbB blockers (e.g. afatinib and canertinib)
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covered in the next section). The most frequently studied
cancer type is NSCLC, followed by BC and HNSCC.
The first report on afatinib in cellular models of lung cancer
initially assessed the effects in two mechanism-based models
exclusively driven by oncogenic EGFR mutations, namely,
anchorage-independent proliferation of NIH-3 T3 murine fi-
broblast cells expressing mutant EGFR and IL-3 independent
proliferation of the Ba/F3 murine pro-B cell line (Li et al.
2008). Afatinib inhibited colony formation of EGFR-
transfected NIH-3 T3 cells in soft agar and was cytotoxic for
Ba/F3 cells, the latter confirmed in an independent study
(Greulich et al. 2012). It also impaired cell survival in several
human NSCLC cell lines, and in each of them, afatinib was
more potent than the reversible inhibitors erlotinib, gefitinib
and lapatinib or the irreversible inhibitor canertinib. Many
subsequent studies have confirmed the growth-inhibiting and
cytotoxic properties of afatinib in a wide range of NSCLC cell
lines (Cha et al. 2012; Chang and Wang 2012; Greulich et al.
2012; Kim et al. 2012a, b; Köhler et al. 2012; Lee et al. 2013;
Nanjo et al. 2012; Ninomiya et al. 2013; Pfeifer et al. 2010;
Rho et al. 2011; Solca et al. 2012; Takezawa et al. 2010;Wang
et al. 2012). The greater potency of afatinib compared to
erlotinib, gefitinib, canertinib or lapatinib was also confirmed
in later studies (Ninomiya et al. 2013; Solca et al. 2012;
Takezawa et al. 2010). The cytotoxic effects of afatinib were
selective for cancer cells with ErbB dysregulation (EC50 1.2–
60 nM) as compared to non-malignant cell lines such as Hs-27
human and Balb/c3T3 mouse fibroblasts (EC50 2,835 and
2,105 nM, respectively) (Cha et al. 2012). Of note, not all
NSCLC cell lines are equally sensitive to growth inhibition by
afatinib. In a study of 65 NSCLC cell lines, the growth
inhibitory potency of afatinib varied markedly; it was most
potent in cell lines harbouring overexpressed wild-type, mu-
tated or amplified EGFR or HER2 and much less potent in
those expressing normal levels of EGFR or mutated BRAF,
KRAS or NRAS (Pfeifer et al. 2010). The lower potency of
afatinib in NSCLC lines harbouring mutated KRAS was also
observed by other investigators (Cha et al. 2012), while other
studies revealed that the presence of mutated KRAS had only
a little effect on the potency of afatinib in inhibiting prolifer-
ation and activate caspase-7, a marker of apoptosis induction
(Chen et al. 2012). Because BRAF, KRAS or NRAS muta-
tions have been reported to be non-overlapping with EGFR or
HER2 mutations, these data strongly suggest that afatinib
behaves like a targeted agent that is selective for cell lines
with specific ErbB receptor deregulations and does not affect
other cancer cell lines, unless very high concentrations are
used.
A role for ErbB targeting agents in the treatment of BC has
been well established based on the anti-HER2 monoclonal
antibody trastuzumab. The inhibitory activity of afatinib in
BC cell lines was explored on 49 BC-derived and five non-
malignant breast cell lines (Heiser et al. 2012). The sensitivity
to afatinib varied markedly between lines and was about 100-
fold greater in lines with amplified HER2 expression in com-
parison to those with normal expression. Growth inhibition of
BC cell lines was confirmed in other studies, where afatinib
was consistently more potent than erlotinib, gefitinib,
canertinib or lapatinib (Canonici et al. 2013; Cha et al. 2012;
Solca et al. 2012). Responsiveness of BC cell lines to afatinib
and other HER2 targeting agents was correlated to a specific
pattern of gene expression alteration in response to short-term
drug exposure (O’Neill et al. 2013). If confirmed, such a
functional signature could help in guiding a more specific
use of these agents in breast cancer treatment.
Other studies have explored afatinib in HNSCC cell lines.
In FaDu cells, expressing EGFR, HER2 and ErbB3, afatinib
inhibited proliferation. An increase in the fraction of cells in
the G0/G1 stage of the cell cycle with a concomitant reduction
of the fraction in the S and G2/M phase was observed and
demonstrated the induction of a G1 arrest by afatinib; a small
but statistically significant radiosensitizing effect was also
noticed in that study (Schütze et al. 2007). Interestingly,
pelitinib (EKB-569) has also shown radiosensitizing in vitro
effect in SCC-4 cells, which were apparently mediated by
inhibition of the binding activity of the transcription factor
NF-κB. Inhibition of the NF-κB DNA-binding activity was
also dose-dependently modulated by afatinib and neratinib
(Aravindan et al. 2011). Growth inhibition by afatinib was
further confirmed in additional HNSCC cell lines, and inhibi-
tion of the transcription factor “Epithelial-restricted with ser-
ine box” by small interfering RNA (siRNA) or a low molec-
ular weight inhibitor reduced EGFR and HER2 promoter
activity and potentiated the effects of afatinib in these cells
(Zhang et al. 2013).
Finally, the growth inhibitory effects of afatinib have been
explored in cell lines representing other types of cancer. For
instance, in a study of 11 gastric cancer lines, only two were
sensitive to afatinib and other ErbB TKI, and these were the
only two that exhibited a high level of HER2 expression (Nam
et al. 2012a). Afatinib was confirmed as a potent inhibitor of
HER2 overexpressing gastric cancer cell lines in other studies
(Cha et al. 2012; Tanaka et al. 2012). In a panel of eight biliary
tract cancer cell lines, afatinib exhibited proliferation in low
nanomolar concentrations (Nam et al. 2012b). In two of these
lines, expressing wild-type KRAS, gefitinib and lapatinib
were requiring somewhat higher concentrations; in two other
lines expressing mutated KRAS, afatinib retained its potency,
whereas gefitinib and lapatinib became ineffective. Afatinib
also inhibited growth of nine colorectal cancer cell lines, but
its potency varied considerably across lines and was tightly
correlated with the expression levels of EGFR, HER2 and
ErbB3 (Khelwatty et al. 2011). Growth inhibition by afatinib
was also observed in a panel of pancreatic cancer cell lines
(Ioannou et al. 2011, 2013). While being tested on a smaller
number of cell lines, afatinib exhibited growth inhibition in
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lines representing bladder cancer (Greulich et al. 2012;
Quesnelle and Grandis 2011; Tasi et al. 2012), endometrial
cancer (Greulich et al. 2012), basal cell carcinoma (Eberl et al.
2012) and epidermal cell carcinoma (Cha et al. 2012). In
melanoma cells with RAS or BRAF mutations, afatinib was
found to be ineffective but gained efficacy when used in
combination with other drugs (see below) (Held et al. 2013).
Effects in in vivo model systems
The effects of afatinib in in vivomodels have been extensively
investigated using human tumour xenograft in immunodefi-
cient mice as well as several transgenic mouse models. Many
of these studies were enhanced by ex vivo biomarker analysis
on tissue from tumours developed in such mice. The first
demonstration of in vivo effects of afatinib was based on
xenografts of the epidermoid carcinoma cell line A431; this
model expresses high levels of wild-type EGFR and detect-
able levels of HER2 and had previously been shown to be
sensitive to EGFR-targeted antibody treatment (Li et al.
2008). In this model, daily oral treatment with afatinib for
25 days reduced tumour growth and induced regressions. On a
molecular level, down-regulation of pEGFR and pAkt expres-
sion was observed in treated tumours. In this model, afatinib
was more effective than gefitinib or lapatinib when given at
their respective maximum tolerated doses.
Afatinib-induced tumour shrinkage was also observed in
transgenic mice with inducible expression of the oncogenic
EGFR L858Rmutant in lung epithelium (Regales et al. 2009);
within days, afatinib reduced lung cancer size by more than
80 % as assessed by imaging studies. In another study using
constitutive transgenic expression of EGFR L858R in mouse
lung, afatinib treatment between weeks 11 and 15 completely
prevented the development of lung cancer (Ninomiya et al.
2013). A similar prevention was found in mice with transgenic
expression of the deletion 19 EGFR mutant (delE748-A752)
upon a 4-week treatment. Long-term treatment with afatinib
extended median survival from 119 to 456 days (Ninomiya
et al. 2013). Most importantly, tumour burden control by
afatinib which resulted in extended survival was not only
observed in comparison to vehicle but to gefitinib
(Ninomiya et al. 2013). In transgenic mice with inducible
expression of mutated HER2 in lung epithelium, afatinib also
prevented further tumour growth (Perera et al. 2009). In line
with the mode of action of afatinib, this was accompanied by
decreased phosphorylation levels of HER2 and various sig-
nallingmolecules from the ERK and Akt/mammalian target of
rapamycin (mTOR) pathway, reduced cellular proliferation
(Ki-67) and increased apoptosis.
Similar beneficial effects of afatinib on tumour size were
observed in xenograft models of HNSCC (Schütze et al. 2007),
gastric cancer (Janjigian et al. 2013; Tanaka et al. 2012),
pancreatic cancer (Ioannou et al. 2011), basal cell carcinoma
(Eberl et al. 2012), colon cancer (Poindessous et al. 2011) and
cetuximab-resistant bladder cancer (Quesnelle and Grandis
2011). Several experiments confirmed that treatment with
afatinib reduced tumour volume in xenograft models based
on a variety of NSCLC cell lines (Cha et al. 2012; Kim et al.
2012b; Mack et al. 2013; Ninomiya et al. 2013; Pan et al. 2012;
Perera et al. 2009; Takezawa et al. 2010, 2012; Yang et al.
2012). Taken together, these studies confirmed the promising
in vitro effects of afatinib in in vivo models.
Afatinib and drug resistance
Afatinib like many other ErbB-targeted agents is primarily
effective as a monotherapy in tumours with particular abnor-
malities of the ErbB signalling network. These defects are
essentially confined to overexpression or mutation of ErbB
ligands or their respective receptors. ErbB receptor overex-
pression can be achieved in multiple ways including for
instance gene amplification, epigenetic regulation of gene
expression or defective protein down-regulation.
Downstream molecular defects such as KRAS, BRAF or
PI3K mutations as expected do not confer particular sensitiv-
ity to ErbB targeting agents. The next sections will focus on
treatment resistance mechanisms in NSCLC patients, an indi-
cation in which EGFR-TKIs are approved.
Primary resistance to EGFR-TKIs
Despite the presence of unequivocal ErbB aberrations, prima-
ry resistance—which can be defined as resistance to a drug in
the case of expected efficacy in patients without prior expo-
sure to this drug—occurs in the clinic. Indeed, not all patients
with HER2 amplification respond to trastuzumab; similarly,
the radiographic response rate in NSCLC patients with EGFR
mutations is generally around 70 %. There are mainly two
mechanisms of de novo resistance that have been described so
far in NSCLC: The first one involves drug resistant EGFR
mutations (e.g. exon 20 mutants or rare mutations such as
D761Y or T790M occurring in cis with an activating EGFR
mutation), and the second includes other genetic alternations
that co-occur with an EGFR-activating mutation in NSCLC
tumours. In the preclinical setting, this is well exemplified by
the inactivity of EGFR-TKIs in H1650 cells or tumours
(NSCLC) that harbour a Del 19 EGFR mutation and are at
the same time PTEN-mutated (Sos et al. 2009). Because this
defect results in hyper-activation of PI3K signalling down-
stream of ErbB receptors, it is not surprising that this mecha-
nism contributes to inefficacy of EGFR targeting drugs, in-
cluding afatinib, despite the presence of an activating EGFR
mutation. While many other mechanisms for primary resis-
tance to EGFR-TKI or ErbB targeting monoclonal antibodies
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are plausible (e.g. expression of multidrug resistance chan-
nels, particular metabolizing enzymes, inactivation of tumour
suppressors such as PTEN), none of them has been experi-
mentally validated or confirmed in preclinical models or in
clinical samples.
Secondary resistance to EGFR-TKIs
Secondary resistance is defined by the emergence of resistant
tumour clones under active treatment. A wide spectrum of
molecular abnormalities can contribute to acquired or second-
ary resistance to ErbB targeting agents in NSCLC (Chen
2012; Sequist et al. 2011).
The first discovered and most frequently observed cause
of acquired resistance to gefitinib/erlotinib treatment in
NSCLC patients with L858R or Del 19 mutations (50 %
of all cases) is the emergence of clones carrying additional
EGFR mutations involving the substitution of a threonine
residue by a methionine in position 790 (T790M)
(Engelman and Settleman 2008). Early experiments sug-
gested that the T790M mutation sterically hindered the
binding of TKIs to the EGFR kinase domain (Kobayashi
et al. 2005; Pao et al. 2005). Later studies (Yun et al. 2008)
revoked the concept and showed that gefitinib actually binds
more tightly (5-fold) to the T790M mutant than to EGFR
wild type. Surprisingly, this mutant shows an even greater
binding affinity for ATP, and the authors suggested that
resistance to gefitinib is not attributable to steric blocking
but rather to the increased affinity for ATP. The structure of
the T790M mutant also suggests that it may accommodate
EGFR-TKI such as AEE788 or HKI-272 in different ways.
Therefore, several studies have assessed the effect of T790M,
studied alone or in combination with the activating mutant
L858R, on sensitivity to afatinib. In the first of such studies,
afatinib was somewhat less potent as an inhibitor of in vitro
tyrosine kinase activity for the L858R/T790M double muta-
tion as compared to the L858R single mutation or the wild-
type EGFR; while the double mutation lowered the potency
of gefitinib and lapatinib to the micromolar range, that of
afatinib stayed in the low nanomolar range (Li et al. 2008);
such data were confirmed in later studies (Table 1) (Solca
et al. 2012). Afatinib also inhibited phosphorylation of
EGFR, ERK and Akt in NSCLC cells with the T790M
mutation (Kim et al. 2012a; Köhler et al. 2012; Lee et al.
2013; Ninomiya et al. 2013; Solca et al. 2012; Takezawa et al.
2010, 2012).
Afatinib, but not erlotinib, also inhibited colony formation
of NIH-3 T3 cells ectopically expressing several EGFR mu-
tations including L858R/T790M (Li et al. 2008). In models
more closely reflecting lung cancer, afatinib also inhibited
survival of NSCLC cell lines expressing L858R/T790M
(NCI-H1975) or EGFR E746_A750del (HCC827); while
the latter was also sensitive to erlotinib, the former was
erlotinib-resistant (Li et al. 2008). Growth inhibition of
NSCLC lines harbouring EGFR T790M was also reported
by other investigators (Chang and Wang 2012; Ercan et al.
2012; Ninomiya et al. 2013; Pfeifer et al. 2010; Sos et al.
2010; Takezawa et al. 2010; Wang et al. 2012). As in the
biochemical studies, the T790Mmutation reduced the potency
of afatinib, but it remained effective within the range which
can be achieved by clinically used doses. The inhibitory
effects of afatinib have also been reported in many other
EGFR genotypes (Sos et al. 2010).
Afatinib inhibited tumour growth in mouse xenograft
models harbouring NSCLC cell lines with the T790M muta-
tion; however, the inhibition was only partial and transient (Li
et al. 2008; Ninomiya et al. 2013; Pan et al. 2012; Takezawa
et al. 2012). Besides xenograft experiments, one in vivo ap-
proach to test EGFR mutations consists in using transgenic
mice in which lung cancer development is driven by inducible
expression of the mutant protein. In such models, afatinib was
reported to reduce tumour volume by about half in mice with
L858R/T790M-driven lung cancer (Li et al. 2008). Other
investigators applied this approach independently to induce
lung expression of L858R, T790M and L858R/T790M. In
these studies, the L858R genotype was sensitive and the
T790M-expressing genotypes insensitive to erlotinib
(Regales et al. 2009). While four out of four mice with the
L858R genotype exhibited a complete response to afatinib, six
out of seven with the double-mutated EGFR exhibited minor
tumour regressions (stable disease) and one progressive dis-
ease. Modest activity of afatinib was confirmed in the clinic
(Sun et al. 2013), indicating the limitation of afatinib mono-
therapy in this setting.
While T790M is the most frequent EGFRmutation causing
acquired resistance to reversible ErbB TKIs, other mutations
known to be resistant to these inhibitors have also been
studied. EGFR L718Q and L844V were identified as muta-
tions which are not leading to intrinsic activation of the
receptor but require EGF for driving proliferation and surviv-
al; cells expressing either of these two mutants were sensitive
to afatinib (Ercan et al. 2012). Similarly, acquired resistance to
EGFR-TKI associated with the second site exon 21 mutation,
T854A can be overcome by afatinib in L858R+T854Amodel
systems (Bean et al. 2008).
Loss of addiction to mutant EGFR can also result from a
mere loss of the mutation with simultaneous gain of depen-
dence on other ErbB receptors, a process termed “HER
reprogramming”. Reprogramming occurs in erlotinib-
resistant PC9 clones, and cell survival in the presence of
erlotinib is achieved by reactivation of PI3K/AKT signalling
through a shift towards HER2/HER3 heterodimers. In these
clones, constitutive PI3K/AKT activation was effectively
inhibited by lapatinib (EGFR and HER2 inhibitor) and by
afatinib (EGFR, HER2 and HER4) as well as by the combi-
nation of erlotinib with small interfering RNAs targeting
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HER2 or HER3 (Tabara et al. 2012). In that study, at least 2
out of 11 patients with activating EGFR mutations who had
become refractory to gefitinib treatment displayed EGFR
mutation loss at recurrence in disseminated cancer cells from
pleural effusions. This data suggests that HER reprogramming
could be of relevance in tumours from gefitinib refractory
NSCLC patients. The clinical relevance of this resistance
mechanism is further underlined by the observation that
HER2 is up-regulated in 12 % of erlotinib/gefitinib failures
lacking the EGFR mutation T790M (Takezawa et al. 2012).
This may in part explain the activity of the afatinib/cetuximab
combination (see below).
Besides second site mutations and HER reprogramming,
several other mechanisms of secondary resistance to revers-
ible EGFR-TKI have been described in the literature (Chen
2012; Hammerman et al. 2009; Kanda et al. 2013; Lin and
Bivona 2012; Sequist et al. 2011). These include (1) MET
receptor amplifications (Nanjo et al. 2012), (2) PI3K CA
mutations, (3) EMT (epithelial mesenchymal transformation)
(Hsu et al. 2012), (4) histological SCLC transformation, (5)
activation of AXL, (6) activation of IGF1R-signalling, (7) loss
of PTEN and enhanced expression (Sos et al. 2009) and
activation of (8) integrinβ1 (Kanda et al. 2013) and (9) SRC
(Kanda et al. 2013).
As these resistance mechanisms are not directly related to
ErbB receptor aberrations, monotherapy with a newer gener-
ation of ErbB targeting agents such as afatinib will not suffice
to overcome resistance and drug combinations will be neces-
sary. Selected opportunities are described in a separate section.
Resistance to afatinib
While several EGFR-mutated cell lines resistant to erlotinib or
gefitinib retain sensitivity to afatinib (see above), prolonged
exposure to afatinib can also cause resistance. In one study,
afatinib-resistant PC9 subclones acquired resistance through
T790M mutations with associated changes in the copy num-
ber of the EGFR T790M allele. In vitro, these resistant cell
lines remained EGFR-dependent as demonstrated by siRNA-
mediated down-regulation of EGFR. The xenografts generat-
ed from these afatinib-resistant clones were also insensitive to
afatinib in vivo and represent a model system in which new
treatment options can be tested (Kim et al. 2012b). These data
also suggested that gene dosage of EGFR T790M is an im-
portant determinant of resistance to afatinib. Of note, amplifi-
cation of EGFRT790Mwas also identified as a mechanism of
resistance to dacomitinib (Ercan et al. 2010). Both inhibitors
are covalent binders and the first step, involving binding to the
catalytic cleft of the target prior to covalent engagement to the
cysteine, remains necessary. While both compounds differ
from reversible inhibitors and show greater inhibitory poten-
cy—as ATP competitors—they will face the increased affinity
for ATP of T790M EGFR mutants albeit at a much lesser
extent. Therefore, tumour expression levels of the T790M
mutant protein will impact on efficacy of afatinib and
dacomitinib.
In a second study assessing resistance to afatinib in T790M
containing mutants, it was found that administration of the
drug resulted in an increase in mRNA coding for the cytokine
IL-6 (Kim et al. 2012a, b). In this case, autocrine IL-6 secre-
tion was shown to activate the JAK1/STAT3 pathway (in-
creased pSTAT3 signal in afatinib treated H1975 or PC9-GR
cells), and inhibition of IL-6 or JAK1 restored afatinib sensi-
tivity in vitro. The combination of afatinib and P6, a pan JAK
inhibitor, was tested in vivo in the gefitinib-resistant PC9-GR
NSCLC model which carries a combined Del19 T790M
EGFR mutation (Fig. 3). The enhanced anti-tumour effect of
the combination was further corroborated by immunohisto-
chemical analyses of PCNA (proliferation marker).
Afatinib in resistance to chemotherapy
Platinum doublets remain the mainstay of therapy in lung
cancer. In the EGFR-mutated population, several trials includ-
ing IPASS, EURTAC, LUX-Lung 3 and LUX-Lung 6 have
clearly demonstrated the superiority of ErbB targeting agents
over standard platinum doublets (Langer 2013). Nevertheless,
treatment with for instance permetrexed and cisplatinum will
remain the main second line treatment in this population.
Because EGFR-mutated tumours often remain sensitive to
ErbB targeting agents beyond progression, thus allowing re-
introduction of these agents in later lines of therapy, it is
important to test whether chemotherapy impacts on the sensi-
tivity to these drugs. To this end, cisplatinum-resistant
NSCLC cell lines were generated from lines expressing either
wild-type (A549 and H460) or mutant EGFR (PC-9 and
HCC827) (Rho et al. 2011). Results from investigations
assessing proliferation and induction of apoptosis revealed
that the potency of erlotinib, gefitinib and afatinib and the
apoptotic fractions induced by them were almost identical in
cisplatinum-resistant and parental lines. The objective re-
sponse rate of 61 % observed in LUX-Lung 2 (second line
use of afatinib in EGFRmutant NSCLC patients) confirms the
observation in the clinical setting. Taken together, these data
demonstrate that resistance to classic chemotherapeutic agents
does not necessarily cause resistance to ErbB TKIs.
Afatinib in combination treatments
The use of combination treatments is frequent in oncology and
aims at delaying or even preventing the development of resis-
tance. To this end, non-clinical models have been used to
explore the potential of afatinib in combination with other
drugs. An obvious option is the combination of afatinib with
other ErbB inhibitors. The rationale behind this concept is
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maximization of ErbB pathway silencing. The preferred op-
tion has been to use monoclonal antibodies, such as anti-
EGFR cetuximab and anti-HER-2 trastuzumab, as combina-
tion partner for afatinib taking into account that afatinib blocks
the kinase activity of all active ErbB receptor kinases. In a
transgenic model with lung-directed expression of EGFR
L858/T790M mutation, afatinib showed only moderate effi-
cacy. Minor tumour regressions (some up to 50 %) were
observed in this model (Li et al. 2008; Regales et al. 2009);
however, the combination of afatinib and cetuximab reduced
tumour volume to a much greater extent (eight out of eight
tumours beyond 50 % reduction with six out of eight beyond
80 %) than either drug alone (Regales et al. 2009). This
combination was also more effective than single agent treat-
ments in the H1975 xenograft model harbouring the L858R/
T790M mutation. The combination potential of afatinib with
other EGFR targeting antibodies (panitumumab) was con-
firmed in a second xenograft model (PC9/BR) generated from
a different NSCLC cell line with the same EGFR genotype
(Takezawa et al. 2012). That study furthermore corroborated
the in vivo synergism for both antibodies in in vitro studies. In
these experiments, the combination provided greater inhibi-
tion of phosphorylation of EGFR, HER2, ErbB3, Erk and Akt
than either drug alone.
The afatinib/cetuximab combination may have benefits
beyond the T790M mutation. In an independent study,
afatinib treatment induced complete tumour response in mice
implanted with tumour fragments from a patient with acquired
erlotinib resistance (but lacking T790M), but after cessation of
treatment, tumours progressed within 2 weeks; however,
when the initial treatment consisted of an afatinib/cetuximab
combination, the mice remained in complete remission during
the entire 75-day follow-up (Mack et al. 2013). Additional
observations support the concept of multi-level ErbB receptor
inhibition. EGFR knock-down by siRNA enhanced the
growth inhibitory effect of afatinib or cetuximab in a panel
of five NSCLC cell lines, including those with T790M muta-
tion (Chen et al. 2012). However, in an EGFR-mutated cell
line resistant to EGFR inhibition in vitro most likely due to a
exon 9 deletion in PTEN (H1650), the combination of afatinib
and cetuximab was not effective (Chang and Wang 2012). An
EGFR antibody, ICR62, exhibited supra-additive growth in-
hibition with afatinib in a colorectal cancer cell line (DiFi)
(Khelwatty et al. 2011). The combination of afatinib and
cetuximab has also been evaluated clinically in patients failing
on erlotinib or gefitinib therapy and early results from the
phase I trial showing a 40 % response rate are promising
(Janjigian et al. 2012). Finally, similar synergism may also
apply to HER2 targeting. In a panel of eight BC cell lines, with
or without resistance to lapatinib, the combination of afatinib
with trastuzumab was more effective than either drug alone;
such synergism was also observed in one line from a subset of
Fig. 3 Anti-tumour activity of
the glycolysis inhibitor 2-
deoxy-D-glucose (2DG), afatinib
and their combination as
compared to control (CON) in a
PC9-GR tumour xenograft
model. Upper panel: Mice
bearing PC9-GR xenografts




+++P<0.001 vs. afatinib. Lower
panel: After 5 days of drug
treatment, mice were sacrificed





Reproduced from Kim et al.
(2013)
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four lines with trastuzumab resistance (Canonici et al. 2013).
The clinical results of a trial assessing the combination of
trastuzumab and lapatinib in HER2-positive breast cancer
patients also support the combination paradigm of dual
targeting of HER2 (Blackwell et al. 2010). All these examples
are in concordance with the concept that maximal ErbB path-
way inhibition can be achieved with a combination of a
monoclonal antibody and a small molecule targeting the same
dysfunctional ErbB receptor.
Afatinib was not only tested in combination with inhibitors
of ErbB receptors but also with inhibitors targeting specific
downstream molecules in the signalling pathway, e.g. MEK,
Akt, PI3K, mTOR or STAT3. For instance, in a bladder cancer
cell line (5637), harbouring a S310F mutation of HER2,
afatinib alone had a little effect on cell survival, but in the
presence of an inhibitor of MEK, which did not affect survival
on its own, afatinib became a 10-fold more potent inhibitor
(Greulich et al. 2012). In an NSCLC model (H1975, EGFR
T790M), combinations of afatinib with a MEK inhibitor
(PD032901), a SRC inhibitor (dasatinib) or a PI3K inhibitor
(PI-103) showed additive effects on induction of apoptosis,
although this did not reach statistical significance (Sos et al.
2010). Dasatinib, an inhibitor of BCR-Abl kinase and SRC
kinase, exhibited synergistic growth inhibition with afatinib in
NSCLC lines expressing L858R/T790M or the combination
of del E746-A750 with a deletion of exon 9 in PTEN (Chang
and Wang 2012). In BRAF mutant melanoma cell lines,
afatinib also had a little effect as a single agent but became a
more potent growth inhibitor in the presence of Akt inhibitors
(GSK690693 and MK-2206) (Held et al. 2013). Pfeifer and
colleagues have systematically explored the compound com-
bination PI-103 (dual PI3K/mTOR inhibitor) with afatinib on
a panel of 65 NSCLC cell lines (Pfeifer et al. 2010). The
authors identified 11 cell lines for which the combination
Fig. 4 Synergistic growth
inhibition of human pancreatic
cancer cells following treatment
with a combination of afatinib and
the IGF-IR inhibitor NVP-
AEW541. aBxPc3, bAsPc-1 cell
line. Reproduced from Ioannou
et al. (2013)
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treatment was synergistic. Amplifications or mutations in
either EGFR or ERBB2 were not enriched in this subset of
cell lines, suggesting a preferential engagement of PI3K sig-
nalling downstream of activated EGFR and HER2. The com-
bination of afatinib with the JAK1 inhibitor P6 was synergistic
with regard to apoptosis induction in a NSCLC cell line
harbouring EGFR T790M (Kim et al. 2012a; Sos et al.
2010), supporting the finding described in Fig. 3. The role
of mTOR was specifically assessed in several studies using
the mTORC1 inhibitor rapamycin. This combination was
reported to be synergistic for in vivo inhibition of lung cancer
growth in a transgenic EGFR L858R/T790M model (Li et al.
2008) and in transgenic as well as xenograft HER2 mutant
models (Perera et al. 2009). Inhibition of glycolysis using 2-
deoxy-D-glucose sensitized NSCLC cells with EGFR T790M
mutation to afatinib via translational suppression of Mcl-1 by
activation of AMP-activated protein kinase (Kim et al. 2013).
This long list of examples demonstrates that afatinib provides
ample opportunities for combinations with targeted agents.
Finally, afatinib has also been explored in combinations
with agents not directly acting on ErbB receptors or their
signalling pathway. For example, afatinib in combination with
the chemotherapeutic drugs 5-fluorouracil or permetrexed,
which target thymidylate synthase, synergistically inhibited
proliferation of a gefitinib-resistant, T790M-expressing
NSCLC cell line, likely due to afatinib-induced suppression
of enzyme expression (Takezawa et al. 2010). In that study,
afatinib was also synergistic with permetrexed and with a
thymidylate synthase inhibitor in an in vivo xenograft model;
in contrast, gefitinib did not exhibit such synergism. In an
in vitro study with colorectal cancer cell lines, the combina-
tion of afatinib with 5-fluouracil was antagonistic in three
lines, but additive or even synergistic in two others
(Khelwatty et al. 2011). The combination of afatinib with
the VEGF antibody bevacizumab was found to be superior
to either drug alone in mice harbouring NSCLC xenografts
with an EGFR exon 19 deletion/T790M or with a L858R/
T790M mutation (Ninomiya et al. 2013). In a panel of seven
pancreas cancer cell lines, afatinib caused synergistic growth
inhibition when combined with an insulin-like growth factor
receptor antibody (Ioannou et al. 2013) (Fig. 4).
In HNSCC cell lines, inhibition of the transcription factor
ESX (epithelial-restricted with serine box) by siRNA or by a
low molecular weight inhibitor reduced EGFR and HER2
promoter activity; the growth-inhibiting effects of these ap-
proaches were enhanced by afatinib (Zhang et al. 2013).
Radiation treatment of bladder cancer cells dose-dependently
induced phosphorylation of EGFR, HER2 and Akt; in a
colony formation assay, afatinib showed synergism with radi-
ation in such cells, indicating possible radiosensitization (Tasi
et al. 2012). A minor radiosensitization by afatinib had also
been observed in HNSCC cell lines (Aravindan et al. 2011;
Schütze et al. 2007).
Conclusions
The preclinical data summarized in this review demonstrate
that the irreversible pan-ErbB TKI afatinib is effective against
a wide range of cancers driven by aberrant ErbB receptor
signalling. Afatinib also shows activity against cancers resis-
tant to first-generation EGFR inhibitors due to certain activat-
ing EGFR mutations, secondary EGFR mutations such as
T790M or tumours expressing other ErbB family receptors
activated by drug-induced reprogramming of signalling path-
ways. Afatinib has recently been approved in several countries
for the treatment of patients with a distinct type of EGFR-
mutated non-small cell lung cancer. A multitude of clinical
trials examining afatinib in lung cancer as well as additional
cancer types and in combination with a variety of established
or investigational agents is currently on-going; the results of
these studies will reveal its full potential to improve treatment
outcomes for a large number of cancer patients with abnor-
malities of the ErbB network.
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